WO1995030675A1 - Biphenylcarboxamides useful as 5-ht1d antagonists - Google Patents
Biphenylcarboxamides useful as 5-ht1d antagonists Download PDFInfo
- Publication number
- WO1995030675A1 WO1995030675A1 PCT/EP1995/001578 EP9501578W WO9530675A1 WO 1995030675 A1 WO1995030675 A1 WO 1995030675A1 EP 9501578 W EP9501578 W EP 9501578W WO 9530675 A1 WO9530675 A1 WO 9530675A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- methyl
- biphenyl
- methoxy
- carboxamide
- hydrogen
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D453/00—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
- C07D453/02—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing not further condensed quinuclidine ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
Definitions
- the present invention relates to novel amide derivatives, processes for their preparation, and pharmaceutical compositions containing them.
- EPA 0533 266 7/8 disclose a series of benzanilide derivatives which are said to possess 5HT ⁇ ⁇ -) receptor antagonist activity. These compounds are said to be of use in the treatment of various CNS disorders.
- the present invention therefore provides a compound of formula (I) or a salt thereof:
- A is CONR where R is hydrogen or C- ⁇ alkyl
- B is oxygen, S(O)q where q is 0, 1 or 2, or B is NR - where R*- 1 is hydrogen or
- C ⁇ _6_dkyl or B is CH2 when R? and R form a group D;
- R* is hydrogen, halogen, C ⁇ galkyl, C3_5cycloalkyl, COC ⁇ _5__lkyl, Ci-galkoxy, hydroxy, hydroxyCi-galkyl, hydroxyCi-galkoxy, Ci.galkoxyCi.galkoxy, acyl, nitro, trifluoromethyl, cyano, SR 9 , SOR 9 , SO 2 R 9 , SO2NRI-R 11 , CO 2 R 10 . CONR 10 R--,
- R2 and R 3 are independently hydrogen, halogen, C1.5a.kyl, C3_5cycloalkyl, C3_5cycloalkenyl, C1.5a.koxy, acyl, aryl, acyloxy, hydroxy, nitro, trifluoromethyl, cyano,
- R ⁇ and R ⁇ are independently hydrogen or Cj ⁇ alkyl
- CR 14 CR- 5 CR 14 R 15 or (CR 14 R 15 )b where b is 2 or 3 and R 14 and R 15 are independently hydrogen or C1.5a.kyl; m is O, 1, 2 or 3; n is 1 or 2; and
- R- is a group of formula (i):
- R° is a group of formula (ii):
- R*- is hydrogen or C1.5a.kyl.
- C ⁇ _5-dkyl groups may be straight chain or branched.
- R- is hydrogen, halogen, C ⁇ _5alkyl, C3.5cycloa.kyl, COC1.5a.kyl, C ⁇ _6alkoxy, hydroxy, hydroxy C ⁇ _5__lkyl, hydroxyC ⁇ _5alkoxy, C ⁇ _5alkoxyC ⁇ _5alkoxy, acyl, nitro, trifluoromethyl, cyano, SR 9 , SOR 9 , SO2R 9 , SO2NR 10 R l l , CO2R 10 , CONRiOR 11 , CO 2 NR 1( -R 1 -, CONR 1 0(CH 2 ) a CO2R 11 , (CH2) a NR 10 R 11 , (CH 2 ) a CONRl ⁇ Rl -, (CH 2 ) a NR 10 CORl-, (CH2) a CO2Ci.6alkyl, CO 2 (CH 2 ) a OR-0, NR 10 R--, NRIOCO
- heterocyclic rings examples include thienyl, furyl, pyrrolyl, triazolyl, diazolyl, imidazolyl, oxadiazolyl, isothiazolyl, isoxazolyl, thiadiazolyl, pyridyl, pyrimidyl and pyrazinyl. These heterocyclic rings can be linked to the remainder of the molecule via a carbon atom or, when present, a nitrogen atom.
- Optional substituents for such rings include R 2 and R 3 groups defined above, preferred substituents include C1.5a.kyl-
- R- is oxadiazolyl, most preferably a 5-methyl-l,2,4-oxadiazol-3-yl group.
- R 2 and R 3 are independently hydrogen, halogen, C ⁇ _6alkyl, C3.5cyclo_-.kyl, C3_5cycloalkenyl, C1.5a.koxy, acyl, aryl, acyloxy, hydroxy, nitro, trifluoromethyl, cyano, CO2R 11 , CONR 12 R 13 , NR 12 R 13 where R 11 , R 12 and R 13 are independently hydrogen or C ⁇ _6alkyl.
- R 2 is Ci_5alkyl, in particular methyl.
- R 3 is hydrogen.
- R 4 and R- are independently hydrogen or C ⁇ _6alkyl.
- R 4 and R ⁇ are both hydrogen.
- R- is hydrogen, halogen, hydroxy, C1.5_.lkyl or C1.5a.koxy.
- R- is C ⁇ _5alkoxy such as methoxy.
- R ⁇ is hydrogen or C ⁇ _6_dkyl, preferably R ⁇ is hydrogen.
- R ⁇ is a group of formula (i) or (ii).
- R ⁇ is a group of formula (i) p, q and r are preferably 2.
- R* is a group of formula (ii) where s is 1 and R* - is C1.5a.kyl such as methyl.
- A is CONR where R is hydrogen or C1.5_.lkyl, that is to say A forms an amide linkage.
- R is hydrogen.
- R 14 and R.15 ajg Preferably D is an ethyl linkage, that is to say forms part of an indoline ring.
- B is oxygen, S(O) q where q is 0, 1 or 2, or B is NR 10 where R 10 is hydrogen or C1.5a.kyl or B is CH2 when R ⁇ and R form a group D.
- B is oxygen.
- n is 1 or 2, preferably n is 1.
- Preferred salts of the compounds of formula (I) are pharmaceutically acceptable salts. These include acid addition salts such as hydrochlorides, hydrobromides, phosphates, acetates, fumarates, maleates, tartrates, citrates, oxalates, methanesulphonates and p-toluenesulphonates.
- acid addition salts such as hydrochlorides, hydrobromides, phosphates, acetates, fumarates, maleates, tartrates, citrates, oxalates, methanesulphonates and p-toluenesulphonates.
- Certain compounds of formula (I) are capable of existing in stereoisomeric forms.
- the present invention provides a process for the preparation of a compound of formula (I) which comprises. (a) for compounds where A is an amide linkage CONR9 reaction of a compound of formula (II):
- R* 7 is an activated carboxylic acid derivative, such as an acyl halide or acid anhydride, and R* - is an amine group.
- (DI) can also be prepared by reaction of the corresponding carboxylic acid with a coupling reagent such as carbonyldiimidazole, dicyclohexylcarbodiimide or diphenylphosphorylazole.
- R* 7 is a group COL where L is halo, particularly chloro.
- a compound of formulae (II) and (HI) are typically reacted together in an inert organic solvent such as DMF, THF or dichloromethane at ambient or elevated temperature in the presence of a base such as an alkali metal hydroxide, triethylamine or pyridine.
- a base such as an alkali metal hydroxide, triethylamine or pyridine.
- Compounds of formula (II) and (TV) are reacted together using similar reaction conditions to those for compounds (II) and (HI).
- Certain compounds of formula (I) can be converted into further compounds of formula (I) using standard procedures.
- 5HTi£) Antagonists and in particular the compounds of the present invention, are expected to be of use in the treatment of CNS disorders such as mood disorders, including depression, seasonal effective disorder and dysthymia; anxiety disorders, including generalised anxiety, panic disorder, agoraphobia, social phobia, obsessive compulsive disorder and post-traumatic stress disorder; memory disorders, including dementia, amnestic disorders and age-associated memory impairment; and disorders of eating behaviours, including anorexia nervosa and bulimia nervosa.
- Other CNS disorders include Parkinson's disease, dementia in Parkinson's disease, neuroleptic-induced Parkinsonism and tardive dyskinesias, as well as other psychiatric disorders.
- 5HT D Antagonists may also be of use in the treatment of endocrine disorders such as hyperprolactinaemia, in the treatment of vasospasm (particularly in the cerebral vasculature) and hypertension, as well as disorders in the gastrointestinal tract where changes in motility and secretion are involved. They may also be of use in the treatment of sexual dysfunction.
- the present invention provides a compound of general formula (I) or a physiologically acceptable salt or solvate thereof for use in therapy.
- the present invention also provides a compound of general formula (I) or a physiologically acceptable salt or solvate thereof for use in the treatment of the aforementioned disorders.
- the invention provides the use of a compound of general formula (I) or a pharmaceutically acceptable salt or solvate thereof for the manufacture of a medicament for the treatment of the aforementioned disorders.
- the invention provides a method of treating the aforementioned disorders which comprises administering an effective amount to a patient in need of such treatment of a compound of general formula (I) or a pharmaceutically acceptable salt or solvate thereof.
- the invention provides a compound of general formula (I) or a physiologically acceptable salt or solvate thereof for use in the treatment or prophylaxis of depression.
- the compounds according to the invention may advantageously be used in conjunction with one or more other therapeutic agents, for instance, different antidepressant agents.
- the present invention also provides a pharmaceutical composition, which comprises a compound of formula (I) or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.
- a pharmaceutical composition of the invention which may be prepared by admixture, suitably at ambient temperature and atmospheric pressure, is usually adapted for oral, parenteral or rectal administration and, as such, may be in the form of tablets, capsules, oral liquid preparations, powders, granules, lozenges, reconstitutable powders, injectable or infusible solutions or suspensions or suppositories. Orally administrable compositions are generally preferred.
- Tablets and capsules for oral administration may be in unit dose form, and may contain conventional excipients, such as binding agents, fillers, tabletting lubricants, disintegrants and acceptable wetting agents.
- the tablets may be coated according to methods well known in normal pharmaceutical practice.
- Oral liquid preparations may be in the form of, for example, aqueous or oily suspension, solutions, emulsions, syrups or elixirs, or may be in the form of a dry product for reconstitution with water or other suitable vehicle before use.
- Such liquid preparations may contain conventional additives such as suspending agents, emulsifying agents, non-aqueous vehicles (which may include edible oils), preservatives, and, if desired, conventional flavourings or colorants.
- fluid unit dosage forms are prepared utilising a compound of the invention or pharmaceutically acceptable salt thereof and a sterile vehicle.
- the compound depending on the vehicle and concentration used, can be either suspended or dissolved in the vehicle.
- the compound can be dissolved for injection and filter sterilised before filling into a suitable vial or ampoule and sealing.
- adjuvants such as a local anaesthetic, preservatives and buffering agents are dissolved in the vehicle.
- the composition can be frozen after filling into the vial and the water removed under vacuum.
- Parenteral suspensions are prepared in substantially the same manner, except that the compound is suspended in the vehicle instead of being dissolved, and sterilisation cannot be accomplished by filtration.
- the compound can be sterilised by exposure to ethylene oxide before suspension in a sterile vehicle.
- a surfactant or wetting agent is included in the composition to facilitate uniform distribution of the compound.
- the composition may contain from 0.1% to 99% by weight, preferably from 10 to 60% by weight, of the active material, depending on the method of administration.
- the dose of the compound used in the treatment of the aforementioned disorders will vary in the usual way with the seriousness of the disorders, the weight of the sufferer, and other similar factors.
- suitable unit doses may be 0.05 to 1000 mg, more suitably 1.0 to 200 mg, and such unit doses may be administered more than once a day, for example two or three a day. Such therapy may extend for a number of weeks or months.
- the title compound was prepared from 2-(l-tert-butpxycarbonylazetidin-2-ylmethoxy)-4- nitroanisole (D9) using the procedure of Description 2 (100%). This material was used in the next step without purification.
- the title compound was prepared from 3-(l-tert-butoxycarbonylazetidin-2-ylmethoxy)-4- methoxyaniline (D10) using the procedure of Description 6 (85%).
- the title compound was prepared from 3-(l-tert.-butoxycarbonylazetidin-2-ylmethoxy)-4- methoxyaniline (D10) using the procedure of Example 1. Purification by chrorratography on silica gel eluting with 0-30% ethyl acetate/ether afforded the title compound as a pale yellow oil (51%).
- the title compound (0.90g, 81 ) was prepared as a light brown solid from l-methyl-3-(2- me oxy-5-nitrophenoxy)pyrrolidine (D20, 1.2g, 0.005 mol), using the method of Description 2.
- l-Methyl-3-piperidinemethanol (2.0g, 0.016 mole) in dry DMF (50 ml) was added dropwise to a suspension of sodium hydride (0.51g of an 80% dispersion in oil, 0.017 mole) in dry DMF (20 ml) under argon and the mixture stirred for 0.5 h.
- l-Fluoro-4- nitrobenzene (2.4g, 0.018 mole) in dry DMF (20 ml) was added dropwise and the mixture stirred at ambient temperature for 18 h. Water was added dropwise until effervescence ceased and the mixture extracted into Et2 ⁇ .
- the tide compound (0.13 g, 76%) as a brown oil was prepared from 5-methoxy-6-(2-(l- methylpyrrolidin-2-yl)ethyl)-lH-indole (D42) (0.17g, 0.7 mmol) using the method of Description 34, and used without purification in the next step.
- the tide compound was prepared from 4-methoxy-3-((R)-l-methylpyrrolidin-2- ylmethoxy)aniline (D6) using the procedure of Example 1. Purification by chromatography on silica gel eluting with 5% methanol/chloroform followed by crystallisation from ethyl acetate/60-80 petrol afforded the tide compound as a white solid (12%) m.pt. 150-151° C.
- the tide compound was prepared from 4-methoxy-3-(l-methylazetidin-2- ylme oxy)aniline (DI 1) using the procedure of Example 1. Purification by chromatography on silica gel eluting with 5% methanol/chloroform followed by crystallisation from ethyl acetate/60-80 petrol, afforded the tide compound as a white solid (9%) m.pt. 160-161° C.
- the oil was purified by silica-gel chromatography (9385, 6%, MeOH/CH2Cl2 as eluant) to give the tide compound as a colourless oil (0.084g, 49%), which was converted to its oxalate salt, m.pt. 154-160°C.
- the tide compound (0.38g, 45%) was prepared as a cream solid from 4-methoxy-3-(l- methylpyrrolidin-3-yloxy)aniline (D21, 0.38g, 0.0017 mol), using the method of Example 9.
- the title compound was prepared from 4-med ⁇ oxy-3-(3-quinuclidinyloxy)aniline (D23) using the procedure of Example 1. Purifiation by chromatography on silica gel eluting witii 5% methanol/chloroform, followed by passage through a short basic alumina column eluting with ethyl acetate, afforded the title compound as a colourless oil. This was convened to its oxalate salt and crystallised from a mixture of methanol/acetone/ether as a white solid (27%), m.pt. 110-113°C.
- the tide compound was prepared from 4-(l-med ⁇ ylpiperidin-3-ylmethoxy)aniline (D31) using the method of Example 1. Reciystallisation from ethyl acetate/petroleum ether gave a white solid (0.18g, 36%).
- the tide compound was prepared from 5-chloro-2,3-dihydro-6-(l-methylpyrrolidin-2- ylmethoxy)-lH-indole (D34) using the procedure of Example 13. Purification by chromatography on silica gel eluting with methanol/chloroform afforded the tide compound as an off-white foam (10%) which was converted to the oxalate salt, m.pt. 102- 105° C.
- the tide compound (0.067g, 25%) was prepared from 2,3-dihydro-5-methoxy-6-(2-(l- methylpyrrolidin-2-yl)ethyl)-lH-indole (D43) (0.13g, 0.5 mmol) using the method of Example 1.
Abstract
Description
Claims
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP95918611A EP0758330A1 (en) | 1994-05-06 | 1995-04-25 | Biphenylcarboxamides useful as 5-ht1d antagonists |
JP7528640A JPH09512804A (en) | 1994-05-06 | 1995-04-25 | Biphenylcarboxamides useful as 5-HT1D antagonists |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB9409068A GB9409068D0 (en) | 1994-05-06 | 1994-05-06 | Novel compounds |
GB9409061A GB9409061D0 (en) | 1994-05-06 | 1994-05-06 | Novel compounds |
GB9409061.0 | 1994-05-06 | ||
GB9409068.5 | 1994-05-06 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO1995030675A1 true WO1995030675A1 (en) | 1995-11-16 |
Family
ID=26304837
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/EP1995/001578 WO1995030675A1 (en) | 1994-05-06 | 1995-04-25 | Biphenylcarboxamides useful as 5-ht1d antagonists |
Country Status (3)
Country | Link |
---|---|
EP (1) | EP0758330A1 (en) |
JP (1) | JPH09512804A (en) |
WO (1) | WO1995030675A1 (en) |
Cited By (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1997007120A1 (en) * | 1995-08-11 | 1997-02-27 | Smithkline Beecham Plc | Biphenyl(thio)amide and biphenylethan(thi)one derivatives, their preparation and their use as 5-ht1d receptor antagonists |
WO2001068585A1 (en) * | 2000-03-14 | 2001-09-20 | Fujisawa Pharmaceutical Co., Ltd. | Novel amide compounds |
US7125898B2 (en) | 2002-02-12 | 2006-10-24 | Smithkline Beecham Corporation | Nicotinamide derivatives useful as p38 inhibitors. |
US7151118B2 (en) | 2001-10-17 | 2006-12-19 | Glaxo Group Limited | Biphenylcarboxylic amide derivatives as p38-kinase inhibitors |
US7166623B2 (en) | 2001-10-17 | 2007-01-23 | Glaxo Group Limited | 2′-Methyl-5′-(1,3,4-oxadiazol-2-yl)-1,1′-biphenyl-4-carboxamide derivatives and their use as p38 kinase inhibitors |
US7166597B2 (en) | 2000-08-22 | 2007-01-23 | Glaxo Group Limited | Fused pyrazole derivatives being protein kinase inhibitors |
US7183297B2 (en) | 2001-10-17 | 2007-02-27 | Glaxo Group Limited | Biphenyl-derivatives as p38-kinase inhibitors |
US7208629B2 (en) | 2001-10-17 | 2007-04-24 | Glaxo Group Limited | 5′-Carbamoyl-1,1-biphenyl-4-carboxamide derivatives and their use as p38 kinase inhibitors |
US7271289B2 (en) | 2003-04-09 | 2007-09-18 | Smithkline Beecham Corporation | Biphenylcarboxylic amide derivatives as p38 kinase inhibitors |
US7384963B2 (en) | 2001-10-17 | 2008-06-10 | Glaxo Group Limited | 2′-Methyl-5-(1,3,4-oxadiazol-2-yl)1, 1′-biphenyl-4-carboxaide derivatives and their use as p38 kinase |
US7396843B2 (en) | 2001-10-17 | 2008-07-08 | Glaxo Group Limited | 5′-carbamoyl-1,1′-biphenyl-4-carboxamide derivatives and their use as p38 kinase inhibitors |
US7432289B2 (en) | 2001-10-17 | 2008-10-07 | Glaxo Group Limited | 5-Acylamino-1,1′-biphenyl-4-carboxamide derivatives and their use as P38 kinase inhibitors |
US7572790B2 (en) | 2003-04-09 | 2009-08-11 | Smithkline Beecham Corporation | Biphenyl carboxylic amide p38 kinase inhibitors |
US7626055B2 (en) | 2003-04-09 | 2009-12-01 | Smithkline Beecham Corporation | Biphenyl-carboxamide derivatives and their use as p38 kinase inhibitors |
US7642276B2 (en) | 2002-07-31 | 2010-01-05 | Smithkline Beecham Corporation | Fused heteroaryl derivatives for use as P38 kinase inhibitors |
US7838540B2 (en) | 2003-08-11 | 2010-11-23 | Glaxosmithkline Llc | 3-aminocarbonyl, 6-phenyl substituted pyridine-1-oxides as p38 kinase inhibitors |
US9388161B2 (en) | 2013-11-18 | 2016-07-12 | Forma Therapeutics, Inc. | Tetrahydroquinoline compositions as BET bromodomain inhibitors |
US9981901B2 (en) | 2007-06-08 | 2018-05-29 | Fosun Orinove Pharmatech, Inc. | IRE-1α inhibitors |
US10377769B2 (en) | 2013-11-18 | 2019-08-13 | Forma Therapeutics, Inc. | Benzopiperazine compositions as BET bromodomain inhibitors |
WO2020183011A1 (en) | 2019-03-14 | 2020-09-17 | Institut Curie | Htr1d inhibitors and uses thereof in the treatment of cancer |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2004016608A1 (en) * | 2002-08-14 | 2004-02-26 | Neurosearch A/S | Novel quinuclidine derivatives and their use |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0533267A1 (en) * | 1991-09-18 | 1993-03-24 | Glaxo Group Limited | Benzanilide derivatives as 5-HT1D antagonists |
EP0533268A1 (en) * | 1991-09-18 | 1993-03-24 | Glaxo Group Limited | Benzanilide derivatives as 5-HT1D antagonists |
-
1995
- 1995-04-25 WO PCT/EP1995/001578 patent/WO1995030675A1/en not_active Application Discontinuation
- 1995-04-25 JP JP7528640A patent/JPH09512804A/en active Pending
- 1995-04-25 EP EP95918611A patent/EP0758330A1/en not_active Withdrawn
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0533267A1 (en) * | 1991-09-18 | 1993-03-24 | Glaxo Group Limited | Benzanilide derivatives as 5-HT1D antagonists |
EP0533268A1 (en) * | 1991-09-18 | 1993-03-24 | Glaxo Group Limited | Benzanilide derivatives as 5-HT1D antagonists |
Cited By (29)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5972935A (en) * | 1995-08-11 | 1999-10-26 | Smithkline Beecham P.L.C. | Biphenyl(thio)amide and bipennylethan(thi) one derivatives, their preparation and their use as 5-HT1D receptor antagonists |
WO1997007120A1 (en) * | 1995-08-11 | 1997-02-27 | Smithkline Beecham Plc | Biphenyl(thio)amide and biphenylethan(thi)one derivatives, their preparation and their use as 5-ht1d receptor antagonists |
WO2001068585A1 (en) * | 2000-03-14 | 2001-09-20 | Fujisawa Pharmaceutical Co., Ltd. | Novel amide compounds |
US7166597B2 (en) | 2000-08-22 | 2007-01-23 | Glaxo Group Limited | Fused pyrazole derivatives being protein kinase inhibitors |
US7396843B2 (en) | 2001-10-17 | 2008-07-08 | Glaxo Group Limited | 5′-carbamoyl-1,1′-biphenyl-4-carboxamide derivatives and their use as p38 kinase inhibitors |
US7151118B2 (en) | 2001-10-17 | 2006-12-19 | Glaxo Group Limited | Biphenylcarboxylic amide derivatives as p38-kinase inhibitors |
US7166623B2 (en) | 2001-10-17 | 2007-01-23 | Glaxo Group Limited | 2′-Methyl-5′-(1,3,4-oxadiazol-2-yl)-1,1′-biphenyl-4-carboxamide derivatives and their use as p38 kinase inhibitors |
US7183297B2 (en) | 2001-10-17 | 2007-02-27 | Glaxo Group Limited | Biphenyl-derivatives as p38-kinase inhibitors |
US7208629B2 (en) | 2001-10-17 | 2007-04-24 | Glaxo Group Limited | 5′-Carbamoyl-1,1-biphenyl-4-carboxamide derivatives and their use as p38 kinase inhibitors |
US7432289B2 (en) | 2001-10-17 | 2008-10-07 | Glaxo Group Limited | 5-Acylamino-1,1′-biphenyl-4-carboxamide derivatives and their use as P38 kinase inhibitors |
US7309800B2 (en) | 2001-10-17 | 2007-12-18 | Glaxo Group Limited | Biphenylcarboxylic amide derivatives as p38 kinase inhibitors |
US7384963B2 (en) | 2001-10-17 | 2008-06-10 | Glaxo Group Limited | 2′-Methyl-5-(1,3,4-oxadiazol-2-yl)1, 1′-biphenyl-4-carboxaide derivatives and their use as p38 kinase |
US7514456B2 (en) | 2002-02-12 | 2009-04-07 | Smithkline Beecham Corporation | Nicotinamide derivatives useful as p38 inhibitors |
US7125898B2 (en) | 2002-02-12 | 2006-10-24 | Smithkline Beecham Corporation | Nicotinamide derivatives useful as p38 inhibitors. |
US7709506B2 (en) | 2002-02-12 | 2010-05-04 | Glaxosmithkline Llc | Nicotinamide derivatives useful as p38 inhibitors |
US7642276B2 (en) | 2002-07-31 | 2010-01-05 | Smithkline Beecham Corporation | Fused heteroaryl derivatives for use as P38 kinase inhibitors |
US7271289B2 (en) | 2003-04-09 | 2007-09-18 | Smithkline Beecham Corporation | Biphenylcarboxylic amide derivatives as p38 kinase inhibitors |
US7572790B2 (en) | 2003-04-09 | 2009-08-11 | Smithkline Beecham Corporation | Biphenyl carboxylic amide p38 kinase inhibitors |
US7626055B2 (en) | 2003-04-09 | 2009-12-01 | Smithkline Beecham Corporation | Biphenyl-carboxamide derivatives and their use as p38 kinase inhibitors |
US7838540B2 (en) | 2003-08-11 | 2010-11-23 | Glaxosmithkline Llc | 3-aminocarbonyl, 6-phenyl substituted pyridine-1-oxides as p38 kinase inhibitors |
US9981901B2 (en) | 2007-06-08 | 2018-05-29 | Fosun Orinove Pharmatech, Inc. | IRE-1α inhibitors |
US9388161B2 (en) | 2013-11-18 | 2016-07-12 | Forma Therapeutics, Inc. | Tetrahydroquinoline compositions as BET bromodomain inhibitors |
US10336722B2 (en) | 2013-11-18 | 2019-07-02 | Forma Therapeutics, Inc. | Tetrahydroquinoline compositions as BET bromodomain inhibitors |
US10377769B2 (en) | 2013-11-18 | 2019-08-13 | Forma Therapeutics, Inc. | Benzopiperazine compositions as BET bromodomain inhibitors |
US10611750B2 (en) | 2013-11-18 | 2020-04-07 | Forma Therapeutics, Inc. | Tetrahydroquinoline compositions as bet bromodomain inhibitors |
US10703764B2 (en) | 2013-11-18 | 2020-07-07 | Forma Therapeutics, Inc. | Benzopiperazine compositions as BET bromodomain inhibitors |
US11084831B1 (en) | 2013-11-18 | 2021-08-10 | Forma Therapeutics, Inc. | Benzopiperazine compositions as BET bromodomain inhibitors |
US11111229B2 (en) | 2013-11-18 | 2021-09-07 | Forma Therapeutics, Inc. | Tetrahydroquinoline compositions as BET bromodomain inhibitors |
WO2020183011A1 (en) | 2019-03-14 | 2020-09-17 | Institut Curie | Htr1d inhibitors and uses thereof in the treatment of cancer |
Also Published As
Publication number | Publication date |
---|---|
EP0758330A1 (en) | 1997-02-19 |
JPH09512804A (en) | 1997-12-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO1995030675A1 (en) | Biphenylcarboxamides useful as 5-ht1d antagonists | |
AU2006242950B2 (en) | Phenoxypropylpiperidines and -pyrrolidines and their use as histamine H3 -receptor ligands | |
US5919932A (en) | Biphenylamide derivatives as 5HT1D antagonists | |
US5935951A (en) | 1-acyl-4-aliphatylaminopiperidine compounds | |
JP2003523998A (en) | New compound | |
UA81749C2 (en) | Derivated of phenylpiperazine as serotonin reuptake inhibitorS | |
AU2005265769A1 (en) | 5-substituted-2-phenylamino-benzamides as MEK inhibitors | |
EP0736025B1 (en) | Dyhydrobenzofuranyl-biphenyl carboxamides having 5ht1d antagonistic activity | |
EP0581167B1 (en) | Novel arylglycinamide derivatives and preparative processes therefor and their use for treatment of dysuria | |
EP0883613A1 (en) | Sulfonamide derivatives as 5ht7 receptor antagonists | |
WO1996036620A1 (en) | Diaryldiamine derivatives and their use as delta opioid (ant)-agonists | |
EP0629190A1 (en) | Compounds as calcium channel antagonists | |
EP0716650A1 (en) | Indole and indoline derivatives as 5ht1d receptor antagonists | |
EP1608635A1 (en) | Phenyl sulfone derivatives and their use in the treatment of cns disorders | |
WO1998031677A1 (en) | Novel aromatic amines derived from cyclic amines useful as medicines | |
NO171060B (en) | ANALOGY PROCEDURE FOR THE PREPARATION OF THERAPEUTIC ACTIVE N-CYCLOALKYLALKYL-BENZYLAMINES | |
AU693336B2 (en) | Pyrrolidinyl hydroxamic acid compounds and their production process | |
HU211675A9 (en) | A novel substituted-acetamide compound and a process for the preparation thereof | |
WO1997007120A1 (en) | Biphenyl(thio)amide and biphenylethan(thi)one derivatives, their preparation and their use as 5-ht1d receptor antagonists | |
WO1997007120A9 (en) | Biphenyl(thio)amide and biphenylethan(thi)one derivatives, their preparation and their use as 5-ht1d receptor antagonists | |
AU645917B2 (en) | New N-(isoquinolin-5-ylsulphonyl)azacycloalkanes, process for the preparation thereof, and pharmaceutical compositions containing them | |
JPH03169841A (en) | Aminopropanol derivative, pharmaceutical composition containing same and their production | |
NZ231243A (en) | Diphenylalkylamide derivatives and pharmaceutical compositions thereof | |
AU726686B2 (en) | Phenylethanolaminotetralincarboxamide derivatives | |
WO1995025100A1 (en) | Use of 4-amino-5-chloro-2-methoxybenzoic esters as 5-ht4 agonists |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): JP US |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
ENP | Entry into the national phase |
Ref country code: US Ref document number: 1996 737147 Date of ref document: 19961104 Kind code of ref document: A Format of ref document f/p: F |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1995918611 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 1995918611 Country of ref document: EP |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 1995918611 Country of ref document: EP |